Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pharmaceutical Research

• Publication date

  2018-09-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11095-018-2503-5PMID 30259180
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

  2020cited by this paper
• Intra‐articular nonviral gene therapy in mucopolysaccharidosis I mice

  2018cited by this paper
• In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system

  2018cited by this paper
• Gene editing of MPS I human fibroblasts by co‐delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers

  2018cited by this paper
• Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: Implications for CRISPR/Cas technology.

  2018cited by this paper
• Cationic nanoemulsions as nucleic acids delivery systems.

  2017cited by this paper
• Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model

  2017cited by this paper
• Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation.

  2016cited by this paper
• Development of a physiologically relevant dripping analytical method using simulated nasal mucus for nasal spray formulation analysis☆

  2016cited by this paper
• Nanotechnology applied to treatment of mucopolysaccharidoses

  2016cited by this paper
• Nasal Drug Delivery Systems: An Overview

  2015cited by this paper
• Non viral vectors in gene therapy- an overview.

  2015cited by this paper
• Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.

  2014cited by this paper
• Laronidase-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Promising Formulation for a More Effective Treatment of Mucopolysaccharidosis Type I

  2014cited by this paper
• Blood–brain barrier structure and function and the challenges for CNS drug delivery

  2013cited by this paper
• Surface Engineering of Liposomes for Stealth Behavior

  2013cited by this paper
• Intranasal administration of CNS therapeutics to awake mice.

  2013cited by this paper
• Investigation of the structural organization of cationic nanoemulsion/antisense oligonucleotide complexes.

  2013cited by this paper
• Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid.

  2012cited by this paper
• Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of Anesthesia

  2012cited by this paper
• Mucopolysacccharidoses: From understanding to treatment, a century of discoveries

  2012cited by this paper
• Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice.

  2012cited by this paper
• Current State of Nanoemulsions in Drug Delivery

  2011cited by this paper
• Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.

  2011cited by this paper
• Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfection on Hep G2 cells

  2011cited by this paper
• Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery.

  2010cited by this paper
• Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment

  2010cited by this paper
• Surface modified liposomes for nasal delivery of DNA vaccine.

  2008cited by this paper
• Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.

  2008cited by this paper
• In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier.

  2008cited by this paper
• Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model

  2005cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Liposomal CRISPR/Cas9-Mediated Local Genome Editing for Joint Disease in Mucopolysaccharidosis Type I

  2026cites this paper
• Nanoengineered Innovations on DNA Delivery Systems for Targeted Cancer Therapy

  2025cites this paper
• Advances in locally administered nucleic acid therapeutics

  2025cites this paper
• Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes

  2025cites this paper
• Recent Advances in Cationic Nanoemulsions for Drug Delivery: Preparation, Properties, and Applications.

  2025cites this paper
• Enzyme Encapsulation in Liposomes: Recent Advancements in the Pharmaceutical and Food Sector

  2025cites this paper
• Recent Advances in Nose-to-Brain Gene Delivery for Central Nervous System Disorders

  2025cites this paper
• Formulation, Development, and Characterization of Carboxymethyl Chitosan Triggered Calcium Carbonate Hybrid Microspheres for Sustained Delivery of Quetiapine: In-vitro and Ex-vivo Studies

  2024cites this paper
• Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.

  2024cites this paper
• Nucleic acid drug vectors for diagnosis and treatment of brain diseases

  2023cites this paper
• Gene editing strategies to treat lysosomal disorders: the example of mucopolysaccharidoses.

  2022cites this paper
• Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system

  2022influential citation
• Nanoemulsions as Gene Delivery in Mucopolysaccharidosis Type I—A Mini-Review

  2022cites this paper
• Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA

  2022cites this paper
• Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases

  2022cites this paper
• Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

  2022cites this paper
• Liposomal formulations for treating lysosomal storage disorders.

  2022cites this paper
• Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

  2022cites this paper
• The landscape of CRISPR/Cas9 for inborn errors of metabolism.

  2022cites this paper
• Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

  2022cites this paper
• Nose-to-brain delivery of biologics and stem cells

  2021cites this paper
• Mucopolysaccharidoses type I gene therapy

  2021cites this paper
• Crocetin as New Cross-Linker for Bioactive Sericin Nanoparticles

  2021cites this paper
• Lysosomal storage diseases: current therapies and future alternatives

  2020cites this paper
• Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

  2020cites this paper
• Nanotechnology for pulmonary and nasal drug delivery

  2020cites this paper
• Effect of cerebrospinal fluid circulation on nose-to-brain direct delivery and distribution of caffeine in rats.

  2020cites this paper
• Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice

  2019cites this paper